 CARLSBAD, Calif., Sept. 22, 2022 GLOBE NEWSWIRE -- Design Therapeutics, Inc. Nasdaq: DSGN, a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported that João Siffert, M.D., president and chief executive officer, and Sean Jeffries, Ph.D., chief operating officer, will participate in a fireside chat during the 2022 Jefferies Cell and Genetic Medicine Summit on Thursday, September 29, 2022, at 10:00 a.m. ET in NYC. 